Hostname: page-component-7b9c58cd5d-bslzr Total loading time: 0.001 Render date: 2025-03-16T05:55:01.089Z Has data issue: false hasContentIssue false
  • English
  • Français

Platelet Monoamine Oxidase Activity in Acute Schizophrenia: Relationship to Symptomatology and Neuroleptic Medication

Published online by Cambridge University Press:  29 January 2018

Frank Owen ,
Rachel C. Bourne ,
Timothy J. Crow ,
Eve C. Johnstone  and
Adnam A. Fadhli
Frank Owen
Affiliation:
Clinical Research Centre, Watford Road, Harrow, Middlesex HA1 3UJ
Rachel C. Bourne
Affiliation:
Clinical Research Centre, Watford Road, Harrow, Middlesex HA1 3UJ
Timothy J. Crow
Affiliation:
Clinical Research Centre, Watford Road, Harrow, Middlesex HA1 3UJ
Eve C. Johnstone
Affiliation:
Clinical Research Centre, Watford Road, Harrow, Middlesex HA1 3UJ
Adnam A. Fadhli
Affiliation:
Division of Psychiatry, College of Medicine, Baghdad, Iraq
Get access Rights & Permissions [Opens in a new window]

Summary

Platelet MAO activity was assessed in 35 schizophrenics during a trial of the isomers of flupenthixol. Enzyme activity was unrelated to severity of symptoms, the presence of delusions, hallucinations or thought disorder or to negative symptoms. In a few patients MAO activity fluctuated widely with time, but in the group of patients on medication there was a slow decrease in enzyme activity which was significant after 28 days of treatment. Enzyme activity after 14 days' drug treatment was still correlated with activity before treatment, but after 28 days this significant correlation disappeared. Slow effects of neuroleptic drugs on platelet MAO activity may explain previous findings of reduced activity of the enzyme in schizophrenia.

Type
Papers
Information
The British Journal of Psychiatry , Volume 139 , Issue 1 , July 1981 , pp. 16 - 22
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Becker, R. E. & Shaskan, E. G. (1977) Platelet monoamine oxidase activity in schizophrenic patients. American Journal of Psychiatry, 134, 512–517.Google Scholar
Belmaker, R. H. Ebbesen, K. Ebstein, R. & Rimon, R. (1976) Platelet monoamine oxidase in schizophrenia and manic depressive illness. British Journal of Psychiatry, 129, 226–232.Google Scholar
Berger, P. A. Ginsburg, R. A. & Barchas, J. D. (1978) Platelet monoamine oxidase in chronic schizophrenic patients. American Journal of Psychiatry, 135, 95–98.Google Scholar
Berretini, W. H. Prozialeck, W. & Vogel, W. H. (1978) Decreased platelet monoamine oxidase activity in chronic schizophrenia shown with novel substrates. Archives of General Psychiatry, 35, 600–605.Google Scholar
Berretini, W. H. Vogel, W. H. & Clouse, R. (1977) Platelet monoamine oxidase in chronic schizophrenia. American Journal of Psychiatry, 134, 805–806.Google Scholar
Bond, P. Cundall, R. L. & Falloon, I. R. H. (1979) Monoamine oxidase (MAO) of platelets, plasma, lymphocytes and granulocytes in schizophrenia. British Journal of Psychiatry, 134, 360–365.Google Scholar
Brockington, I. Crow, T. J. Johnstone, E. C. & Owen, F. (1976) An investigation of platelet monoamine oxidase activity in schizophrenia and schizo-affective psychosis. In Monoamine Oxidase and its Inhibition (eds. Wolstenholme, G. E. W. and Knight, J.), pp 353–363. Ciba Foundation Symposium, 39, New Series. New York: Elsevier.Google Scholar
Carpenter, W. T. Murphy, D. L. & Wyatt, R. J. (1975) Platelet monoamine oxidase activity in acute schizophrenia. American Journal of Psychiatry, 132, 438–441.Google ScholarPubMed
Domino, E. F. & Gahagan, S. (1977) In vitro half-life of 14C tryptamine in whole blood of drug-free chronic schizophrenic patients. American Journal of Psychiatry, 134, 1280–1282.Google Scholar
Domino, E. F. & Khanna, S. S. (1976) Decreased blood platelet MAO activity in unmedicated chronic schizophrenic patients. American Journal of Psychiatry, 133, 323–326.Google Scholar
Feighner, J. P. Robins, E. Guze, S. B. Woodruff, R. A. Winokur, G. & Munoz, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 57–63.Google Scholar
Friedhoff, A. J. Miller, J. C. & Weisenfreund, J. (1978) Human platelet MAO in drug-free and medicated schizophrenic patients. American Journal of Psychiatry, 135, 952–955.Google Scholar
Friedman, E. Shopsin, B. Sathananthan, G. & Gershon, S. (1974) Blood platelet monoamine oxidase activity in psychiatric patients. American Journal of Psychiatry, 131, 1392–1394.CrossRefGoogle ScholarPubMed
Johnstone, E. C. Crow, T. J. Frith, C. D. Carney, M. W. P. & Price, J. S. (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet, i, 848–851.CrossRefGoogle Scholar
Krawiecka, M. Goldberg, D. P. & Vaughan, M. (1977) A standardized psychiatric assessment scale for rating chronic psychiatric patients. Acta Psychiatrica Scandinavica, 55, 299.CrossRefGoogle Scholar
Meltzer, H. Y. & Stahl, S. M. (1974) Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients. Research Communications in Chemical Pathology and Pharmacology, 7, 419–431.Google Scholar
Murphy, D. L. Belmaker, R. Carpenter, W. T. & Wyatt, R. J. (1977) Monoamine oxidase in chronic schizophrenia and studies of hormonal and other factors affecting enzyme activity. British Journal of Psychiatry, 130, 151–158.Google Scholar
Murphy, D. L. & Wyatt, R. J. (1972) Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature, 23, 225–226.Google Scholar
Nies, A. Robinson, D. S. Harris, L. S. & Lamborn, K. (1974) Comparison of monoamine oxidase substrate activities in twins, schizophrenics, depressives and controls. In Neuropsychopharmacology of Monoamines and their Regulatory Enzymes (ed. Usdin, E.). New York: Raven Press.Google Scholar
Orsulak, P. J. Schildkraut, J. J. Schatzberg, A. F. & Herzog, J. M. (1978) Differences in platelet monoamine oxidase activity in sub-groups of schizophrenic and depressive disorders. Biological Psychiatry, 13, 637–647.Google Scholar
Owen, F. Bourne, R. C. Crow, T. J. Johnstone, E. C. Bailey, A. R. & Hershon, H. I. (1976) Platelet monoamine oxidase in schizophrenia. Archives of General Psychiatry, 33, 1370–1373.Google Scholar
Schildkraut, J. J. Herzog, J. M. Orsulak, P. J. Edelman, S. E. Shew, H. M. & Frazier, S. H. (1976) Reduced platelet monoamine oxidase activity in a sub-group of schizophrenic patients. American Journal of Psychiatry, 133, 438–440.Google Scholar
Shaskan, E. G. & Becker, R. E. (1975) Platelet monoamine oxidase in schizophrenics. Nature (London), 253, 659–660.Google Scholar
Takahashi, S. Yamane, H. & Naosuke, T. (1975) Reduction of blood platelet monoamine oxidase activity in schizophrenic patients on phenothiazines. Folia Psychiatrica et Neurologica Japonica (Niijata), 29, 207–214.Google Scholar
Sullivan, J. Stanfield, C. N. & Dackis, C. (1977) Platelet MAO activity in schizophrenia and other psychiatric illnesses. American Journal of Psychiatry, 134, 1098–1102.Google Scholar
White, H. L. McLeod, M. N. & Davidson, J. R. T. (1976) Platelet monoamine oxidase activity in schizophrenia. American Journal of Psychiatry, 133, 1191–1193.Google Scholar
Wing, J. K. Cooper, J. E. & Sartorius, N. (1974) The Measurement and Classification of Psychiatric Symptoms, Cambridge University Press.Google Scholar
Wyatt, R. J. Murphy, D. L. Belmaker, R. Cohen, S. Donelly, C. H. & Pollin, W. (1973) Reduced monoamine oxidase activity in platelets: a possible genetic marker for vulnerability to schizophrenia. Science, 179, 916–918.Google Scholar
Wyatt, R. J. Murphy, D. L. (1976) Low platelet monoamine oxidase activity and schizophrenia. Schizophrenia Bulletin, 2, 77–89.Google Scholar
Zeller, E. A. Boshes, B. Davis, J. M. & Thorner, M. (1975) Molecular aberration in platelet monoamine oxidase in schizophrenia. Lancet, i, 1385.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.